Cargando…

Treatment satisfaction and quality of life in patients treated with fingolimod

BACKGROUND: The development of oral treatments for relapsing–remitting multiple sclerosis (RRMS) may alter patient satisfaction and quality of life (QoL). The aim of this survey was to evaluate treatment satisfaction and QoL in patients treated with fingolimod in everyday clinical practice in France...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mékiès, Claude, Heinzlef, Olivier, Jenny, Béatrice, Ramelli, Anne-Laure, Clavelou, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973401/ https://www.ncbi.nlm.nih.gov/pubmed/29872275 http://dx.doi.org/10.2147/PPA.S144021

Ejemplares similares

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod
por: Hanson, Kristin A, et al.
Publicado: (2013)

Fingolimod in children with Rett syndrome: the FINGORETT study
por: Naegelin, Yvonne, et al.
Publicado: (2021)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis – results from a 24-month, multicenter, open-label Danish study
por: Schreiber, Karen, et al.
Publicado: (2018)

Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod
por: Mallucci, Giulia, et al.
Publicado: (2020)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Satisfaction and experiences of patients taking fingolimod and involved in a pharmacy-based patient support program in Switzerland — a qualitative study
por: Bourdin, Aline, et al.
Publicado: (2020)

Life-threatening asthma attack during prolonged fingolimod treatment: case report
por: Zecca, Chiara, et al.
Publicado: (2014)

Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation
por: Benzimra, Michaël, et al.
Publicado: (2018)

A case of presumed herpes keratouveitis in a patient treated with fingolimod
por: Ayers, Malissa C, et al.
Publicado: (2016)

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
por: Hasan Ali, Omar, et al.
Publicado: (2020)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

Fingolimod inhibits multiple stages of the HIV-1 life cycle
por: Resop, Rachel S., et al.
Publicado: (2020)

Progressive multifocal leukoencephalopathy after fingolimod treatment
por: Berger, Joseph R., et al.
Publicado: (2018)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab
por: Kim, Seong-Kyu, et al.
Publicado: (2023)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Foerch, Christian, et al.
Publicado: (2020)

Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod
por: Barbano, Lucilla, et al.
Publicado: (2021)

Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod
por: Ciccone, A., et al.
Publicado: (2023)

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
por: Fukai, Ryoko, et al.
Publicado: (2019)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
por: Feng, Jenny, et al.
Publicado: (2019)

Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)
por: TUNCER, Aslı, et al.
Publicado: (2022)

Evaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis
por: Özsoy-Ünübol, Tuğba, et al.
Publicado: (2020)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Satisfaction of the quality of life in patients with schizophrenia
por: Ouali, R., et al.
Publicado: (2021)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke
por: Li, Wentao, et al.
Publicado: (2016)

The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016)

Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series
por: Del Poeta, Maurizio, et al.
Publicado: (2022)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models
por: Davy, Mélodie, et al.
Publicado: (2023)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hlmq9u2gbvoqvh09f5b07jvm3r